Ubio Biotechnology Systems Profile
Key Indicators
- Authorised Capital ₹ 1.67 Cr
as on 04-07-2024
- Paid Up Capital ₹ 1.43 Cr
as on 04-07-2024
- Company Age 16 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.25 Cr
as on 04-07-2024
- Satisfied Charges ₹ 5.30 M
as on 04-07-2024
- Revenue -69.98%
(FY 2023)
- Profit -99.53%
(FY 2023)
- Ebitda -107.39%
(FY 2023)
- Net Worth 0.52%
(FY 2023)
- Total Assets -4.69%
(FY 2023)
About Ubio Biotechnology Systems
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.67 Cr and a paid-up capital of Rs 1.43 Cr.
The company currently has active open charges totaling ₹2.25 Cr. The company has closed loans amounting to ₹5.30 M, as per Ministry of Corporate Affairs (MCA) records.
Ravinder Qasba, Bishor Varakukalayil, and Brij Qasba serve as directors at the Company.
- CIN/LLPIN
U72200KL2008PTC022851
- Company No.
022851
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jul 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Ubio Biotechnology Systems?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bishor Varakukalayil  | Managing Director | 23-Jul-2008 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ravinder Qasba | Director | 28-Feb-2014 | Current |
| Brij Qasba | Whole-Time Director | 28-Feb-2014 | Current |
Financial Performance of Ubio Biotechnology Systems.
Ubio Biotechnology Systems Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 69.98% decrease. The company also saw a substantial fall in profitability, with a 99.53% decrease in profit. The company's net worth moved up by a moderate rise of 0.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ubio Biotechnology Systems?
In 2023, Ubio Biotechnology Systems had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pamposh Foods India Private LimitedActive 11 years 10 monthsRavinder Qasba and Brij Qasba are mutual person
- Biosix Peptides (India) Private LimitedActive 16 years 1 month
Bishor Varakukalayil is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 20 May 2022 | ₹2.25 Cr | Open |
State Bank Of India Creation Date: 29 Nov 2013 | ₹2.40 M | Satisfied |
State Bank Of India Creation Date: 19 Jul 2011 | ₹2.90 M | Satisfied |
How Many Employees Work at Ubio Biotechnology Systems?
Unlock and access historical data on people associated with Ubio Biotechnology Systems, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ubio Biotechnology Systems, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ubio Biotechnology Systems's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
